Advertisement

Clinical and Experimental Nephrology

, Volume 22, Issue 5, pp 1079–1087 | Cite as

Elevation of the serum liver enzyme levels during tolvaptan treatment in patients with autosomal dominant polycystic kidney disease (ADPKD)

  • Shiho Makabe
  • Toshio Mochizuki
  • Michihiro Mitobe
  • Yumi Aoyama
  • Hiroshi Kataoka
  • Ken Tsuchiya
  • Kosaku NittaEmail author
Original article

Abstract

Background

In 2014, tolvaptan, a vasopressin receptor antagonist, was approved for the treatment of autosomal dominant polycystic kidney disease (ADPKD) in Japan. Clinical trials of tolvaptan revealed frequent occurrence of the liver function abnormality. According to the package insert in Japan, liver function tests should be performed once a month in patients receiving tolvaptan. Furthermore, immediate discontinuation of tolvaptan is recommended in the appearance of liver function abnormalities.

Methods

Seven patients of ADPKD who was discontinued tolvaptan because of elevation of the serum liver enzyme levels were described in detail and analyzed.

Results

None of them fulfilled the criteria for applicability of Hy’s law, which predicts a high risk of severe, potentially fatal, drug-induced liver injury (DILI). In our patients, the rate of increase of total kidney volume (TKV) significantly decreased during tolvaptan administration, but increased after discontinuation; in Cases 1–5, mean annual growth rate of TKV during administration was − 10.15%/year, and during discontinuation was + 23.72%/year. After the serum liver enzyme levels returned to normal range, tolvaptan was resumed in six patients with informed consent. Except one patient, tolvaptan has been continued without increase of the serum liver enzyme levels.

Conclusion

In patients with mild elevation of the serum liver enzyme, as is less than three times the upper limit of normal (ULN), resumption of tolvaptan may be considered after the serum liver enzyme levels return to normal range.

Keywords

ADPKD Tolvaptan Liver injury 

Notes

Acknowledgements

We express our sincere appreciation to all the patients, collaborating physicians, and other medical staff for their important contributions to the study. This study was supported in part by a Grant-in-Aid for Intractable Renal Diseases Research, Research on rare and intractable diseases, Health and Labor Sciences Research Grants from the Ministry of Health, Labor and Welfare of Japan.

Compliance with ethical standards

Conflict of interest

Toshio Mochizuki and Ken Tsuchiya received Travel fees and honoraria for lectures from Otsuka Pharmaceutical Co. Toshio Mochizuki and Hiroshi Kataoka belong to an endowed department sponsored by Otsuka Pharmaceutical Co, Chugai Pharmaceutical Co, Kyowa Hakko Kirin Co, MSD Co, and JMS Co.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee at which the studies were conducted (IRB approval number 140807) and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Mochizuki T, Tsuchiya K, Nitta K. Autosomal dominant polycystic kidney disease: recent advances in pathogenesis and potential therapies. Clin Exp Nephrol. 2013;17(3):317–26.  https://doi.org/10.1007/s10157-012-0741-0.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Gattone VH, Wang X, Harris PC, Torres VE. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med. 2003;9(10):1323–6.  https://doi.org/10.1038/nm935.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407–18.  https://doi.org/10.1056/NEJMoa1205511.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Watkins PB, Lewis JH, Kaplowitz N, Alpers DH, Blais JD, Smotzer DM, et al. Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: analysis of clinical trials database. Drug Saf. 2015;38(11):1103–13.  https://doi.org/10.1007/s40264-015-0327-3.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    SAMSCA® (tolvaptan) Package insert [in Japanese], revised Mar 2017. 2018. http://www.info.pmda.go.jp/downfiles/ph/PDF/180078_2139011D1022_1_01.pdf.
  6. 6.
    JINARC™ (tolvaptan) Product Monograph, Otsuka Canada Pharmaceutical Inc. 2018. http://otsukacanada.com/docs/default-source/default-document-library/jinarc-pm-en-23feb2015_final.pdf?sfvrsn=2.
  7. 7.
    Gigot JF, Jadoul P, Que F, Van Beers BE, Etienne J, Horsmans Y, et al. Adult polycystic liver disease: is fenestration the most adequate operation for long-term management? Ann Surg. 1997;225(3):286–94.CrossRefGoogle Scholar
  8. 8.
    United States Food and Drug Administration. Guidance for industry, drug-induced liver injury: premarketing clinical evaluation. 2014. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM174090.pdf. Accessed 11 Feb 2015.
  9. 9.
    Kim SH, Naisbitt DJ. Update on advances in research on idiosyncratic drug-induced liver injury. Allergy Asthma Immunol Res. 2016;8(1):3–11.  https://doi.org/10.4168/aair.2016.8.1.3.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Woodhead JL, Watkins PB, Howell BA, Siler SQ, Shoda LKM. The role of quantitative systems pharmacology modeling in the prediction and explanation of idiosyncratic drug-induced liver injury. Drug Metab Pharmacokinet. 2017;32(1):40 – 5.  https://doi.org/10.1016/j.dmpk.2016.11.008.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Dara L, Liu ZX, Kaplowitz N. Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury, clinical implications. Liver Int. 2016;36(2):158–65.  https://doi.org/10.1111/liv.12988.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Woodhead JL, Brock WJ, Roth SE, Shoaf SE, Brouwer KL, Church R, et al. Application of a mechanistic model to evaluate putative mechanisms of tolvaptan drug-induced liver injury and identify patient susceptibility factors. Toxicol Sci. 2017;155(1):61–74.  https://doi.org/10.1093/toxsci/kfw193.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Slizgi JR, Lu Y, Brouwer KR, St Claire RL, Freeman KM, Pan M, et al. Inhibition of human hepatic bile acid transporters by tolvaptan and metabolites: contributing factors to drug-induced liver injury? Toxicol Sci. 2016;149(1):237–50.  https://doi.org/10.1093/toxsci/kfv231.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Mosedale M, Kim Y, Brock WJ, Roth SE, Wiltshire T, Eaddy JS et al. Editor’s highlight: candidate risk factors and mechanisms for tolvaptan-induced liver injury are identified using a collaborative cross approach. Toxicol Sci. 2017;156(2):438 – 54.  https://doi.org/10.1093/toxsci/kfw269.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Japanese Society of Nephrology 2018

Authors and Affiliations

  • Shiho Makabe
    • 1
  • Toshio Mochizuki
    • 1
  • Michihiro Mitobe
    • 1
  • Yumi Aoyama
    • 1
  • Hiroshi Kataoka
    • 1
  • Ken Tsuchiya
    • 1
  • Kosaku Nitta
    • 1
    Email author
  1. 1.Department of Internal Medicine, Kidney CenterTokyo Women’s Medical UniversityTokyoJapan

Personalised recommendations